Intero Sends Mini Human Intestines to Drugmakers — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Intero Biosystems sells GastroScreen, a human intestinal organoid roughly 1mm across derived from induced pluripotent stem cells, shipping about 100 per tube to pharma, biotech, food, and chemical customers for drug and compound testing.
- Intero was founded in 2024, has seven employees and just under 10 customers, raised a $2.3 million pre-seed round, and generated more than $400,000 in revenue from Q4 last year through Q3 this year.
- Co-founder Charlie Childs said Intero is in the second of three validation stages, showing GastroScreen responds as expected to drugs that reduce intestinal inflammation and compounds known to damage the gut, and is now comparing results against pharma partners' animal and clinical data.
- The FDA laid out plans in April last year to reduce animal testing reliance and issued draft guidance in March of this year for validating new approach methodologies (NAMs), a shift Intero's co-founder Madeline Eiken said is making once-hesitant pharma companies bring organoid tech in-house.
- Intero competes with Altis Biosystems and InSphero in stem-cell- and patient-derived intestinal models and with MIMETAS in organ-on-chip approaches, but says it differentiates on iPSC-based scalability and personalization from a blood sample.
- Intero doesn't use AI to build organoids but plans to license the biological datasets they generate to pharma and AI companies, and is working to automate manufacturing from a few thousand toward hundreds of thousands of organoids per batch.
- Intero pitched at TechCrunch Disrupt on Wednesday as one of 20 startups competing for this year's Startup Battlefield title; Disrupt runs October 13–15 in San Francisco.
Why it matters: Most drug candidates still fail in clinical trials because species-specific biology doesn't translate from animal models. If Intero and peers can validate organoid-based testing to FDA standards, pharma companies gain a cheaper, more human-relevant preclinical screen while reducing animal use — and Intero captures recurring revenue on both the organoids and the consumables that run experiments.
Ask SkimNews
